Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Source and Purity of Factor VIII Products As Risk Factors for Inhibitor Development In Previously Untreated Patients with Severe Hemophilia A

Maria Elisa Mancuso, MD, PhD, Pier Mannuccio Mannucci, MD, Angiola Rocino, MD, Isabella Garagiola, Annarita Tagliaferri, Elena Santagostino, MD, PhD

Blood (2011) 118 (21): 25.

https://doi.org/10.1182/blood.V118.21.25.25

Published: 2011

Journal Articles

Prophylactic Dosing of Anti-Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors: Results of the Pro-FEIBA Study

Cindy A. Leissinger, MD, Eric Berntorp, MD, Chiara Biasioli, MD, Shannon Carpenter, MD, MS, Hyejin Jo, MS, Kaan Kavakli, MD, Claude Negrier, MD, Angiola Rocino, MD, Jerzy Windyga, MD, Bulent Zulfikar, MD, Alessandro Gringeri, MD

Blood (2010) 116 (21): 720.

https://doi.org/10.1182/blood.V116.21.720.720

Published: 2010

Journal Articles

Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients.

Augusto B. Federici, Paolo Bucciarelli, MD, Alfonso Iorio, Giancarlo Castaman, Maria Gabriella Mazzucconi, Massimo Morfini, Angiola Rocino, MD, Pier M. Mannucci, MD

Blood (2009) 114 (22): 3494.

https://doi.org/10.1182/blood.V114.22.3494.3494

Published: 2009

Journal Articles

Type of Factor VIII Product as Inhibitor Risk Factor in Patients with Severe Hemophilia A and Null Mutations.

Maria Elisa Mancuso, MD, PhD, Pier Mannuccio Mannucci, MD, Angiola Rocino, MD, Isabella Garagiola, PhD, AnnaRita Tagliaferri, MD, Maurizio Margaglione, MD, Elena Santagostino, MD, PhD

Blood (2009) 114 (22): 3500.

https://doi.org/10.1182/blood.V114.22.3500.3500

Published: 2009

Journal Articles

Cardiotoxicity and Treatment Efficacy of Not Pegilated Liposomal Doxorubicin in Haematological Malignancies: Our Experience.

Alfredo Gagliardi, MD, Maria Lucia Boffa, MD, Gaetana Capobianco, MD, Concetta Cotarelli, BD, Donatella De Blasi, MD, Lucia Liguori, MD, Ruggiero Orlando, MD, Angiola Rocino, MD, Maria Maddalena Spiezia, MD, Luigi Ziello, MD, Eustachio Miraglia, MD

Blood (2007) 110 (11): 4836.

https://doi.org/10.1182/blood.V110.11.4836.4836

Published: 2007

Journal Articles

Incidence and Determinants of Bleeding in Different Types of von Willebrand Disease: Results of the First Prospective Multicenter Study on 814 Italian Patients.

Augusto B. Federici, MD, Paolo Bucciarelli, MD, Giancarlo Castaman, MD, Maria G. Mazzucconi, MD, Massimo Morfini, MD, Angiola Rocino, MD, Mario Schiavoni, MD, Francesco Rodeghiero, MD, Pier M. Mannucci, MD

Blood (2007) 110 (11): 713.

https://doi.org/10.1182/blood.V110.11.713.713

Published: 2007

Journal Articles

High Efficacy of Combination Therapy with Pegylated Interferon and Ribavirin in Hemophiliacs with Chronic Hepatitis C.

Maria E. Mancuso, MD, Elena Santagostino, MD, PhD, Maria G. Rumi, MD, Silvia Linari, MD, Antonio Coppola, MD, Angiola Rocino, MD, Alfonso Iorio, MD, Alfredo Dragani, MD, Giovanni Barillari, MD, Giuseppe Tagariello, MD, Roberto Nicolin, MD, Massimo Colombo, MD, Pier M. Mannucci, MD

Blood (2005) 106 (11): 3219.

https://doi.org/10.1182/blood.V106.11.3219.3219

Published: 2005

Journal Articles

A Randomized Crossover Study of High- and Standard-Dose Recombinant Factor VIIa for Treatment of Hemarthroses in Hemophiliacs with Inhibitors.

Elena Santagostino, MD, PhD, Maria E. Mancuso, MD, Angiola Rocino, MD, Giacomo Mancuso, MD, Francesco A. Scaraggi, MD, Massimo Morfini, MD, Filomena Daniele, MD, Giovanni Barillari, MD, Pier M. Mannucci, MD

Blood (2005) 106 (11): 323.

https://doi.org/10.1182/blood.V106.11.323.323

Published: 2005

Journal Articles

Impact of Early Factor VIII Exposure, Prophylaxis and Prenatal/Perinatal Events on Inhibitor Risk in Children with Hemophilia A: A Case-Control Study.

Elena Santagostino, MD, PhD, Angiola Rocino, MD, Maria E. Mancuso, MD, Maria G. Mazzucconi, MD, Giacomo Mancuso, MD, Maria Messina, MD, Annarita Tagliaferri, MD, Matteo Luciani, MD, Elio Boeri, MD, Pier M. Mannucci, MD

Blood (2004) 104 (11): 37.

https://doi.org/10.1182/blood.V104.11.37.37

Published: 2004

NARROW

Source and Purity of Factor VIII Products As Risk Factors for Inhibitor Development In Previously Untreated Patients with Severe Hemophilia A

Prophylactic Dosing of Anti-Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors: Results of the Pro-FEIBA Study

Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients.

Type of Factor VIII Product as Inhibitor Risk Factor in Patients with Severe Hemophilia A and Null Mutations.

Cardiotoxicity and Treatment Efficacy of Not Pegilated Liposomal Doxorubicin in Haematological Malignancies: Our Experience.

Incidence and Determinants of Bleeding in Different Types of von Willebrand Disease: Results of the First Prospective Multicenter Study on 814 Italian Patients.

High Efficacy of Combination Therapy with Pegylated Interferon and Ribavirin in Hemophiliacs with Chronic Hepatitis C.

A Randomized Crossover Study of High- and Standard-Dose Recombinant Factor VIIa for Treatment of Hemarthroses in Hemophiliacs with Inhibitors.

Impact of Early Factor VIII Exposure, Prophylaxis and Prenatal/Perinatal Events on Inhibitor Risk in Children with Hemophilia A: A Case-Control Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only